Ali Tehrani

Ali Tehrani is a seasoned professional in the biotechnology and venture capital sectors, currently serving as a Partner and Venture Partner at Amplitude Ventures since March 2022. Tehrani co-founded DCx Biotherapeutics Corporation in January 2024 and has been a Board Member at Reverb Therapeutics since July 2023, where the focus is on innovative antibody therapeutics for oncology and autoimmune disease. Additional board roles include QurCan Therapeutics Inc. and previously Creatus Biosciences Inc., and Tehrani was Co-founder, President, and CEO of Zymeworks from its inception until January 2022. Tehrani holds a PhD in Microbiology and Immunology from The University of British Columbia and two degrees from the University of Massachusetts Amherst, including a Master’s in Biochemistry and a Bachelor of Applied Science in Biochemistry.